Pfizer licenses gene for possible AMD therapy

December 2006
Ophthalmology Times;12/1/2006, Vol. 31 Issue 23, p8
Trade Publication
The article reports on the acquisition of Pfizer Inc. of the worldwide license to a novel human gene with Quark Biotech Inc. in the U.S. Under the deal, the former will develop the gene called RTP-801, and molecules that modify it that could have the potential to treat neovascular age-related macular degeneration.


Related Articles

  • Quark Signs Research Pact With Shionogi.  // Worldwide Biotech;Mar2000, Vol. 12 Issue 3, p1 

    Reports on the research and license agreement signed by Quark Biotech Inc. and Shionogi & Co. to discover and analyze genes associated with osteoarthritis.

  • Pfizer, UCL form AMD collaboration.  // Ophthalmology Times;6/15/2009, Vol. 34 Issue 12, p6 

    The article reports on the license agreement between Pfizer Inc.'s Regenerative Medicine and the University College London (UCL) in developing cell-based therapies for wet and dry age-related macular degeneration. According to Pfizer Chief Regenerative Medicine Ruth McKernan, the agreement...

  • PFIZER. Investor's Business Daily // Investors Business Daily;10/ 9/2013, pA02 

    The article reports that Pfizer won't pursue a license for Lpath's iSonep, used for treatment of age-related macular degeneration.

  • Sequenom acquires rights to Optherion's AMD genetic tests.  // Medical Device Daily;2/10/2010, Vol. 14 Issue 27, p3 

    The article reports on the exclusive worldwide licensing agreement reached by Sequenom with Optherion in February 2010. It states that the deal will allow the Sequenom Center for Molecular Medicine the rights to manufacture and market diagnostic tests to predict genetic predisposition to late...

  • Global Age-Related Macular Degeneration Drug Pipeline Capsule -- 2011.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p32 

    The article presents the report of Fore Pharma entitled "Global Age-Related Macular Degeneration Drug Pipeline Capsule-2011." The report outlines the primary research and development (R&D) activities of the age-related macular degeneration drug market. It is also upgraded with the full coverage...

  • Seattle Genetics Inks $200M Licensing Deal with Pfizer.  // Bioworld Week;1/10/2011, Vol. 19 Issue 2, p5 

    The article focuses on the 200 million dollars licensing deal with Seattle Genetics Inc. and Pfizer Inc. for the Seagen's antibody-drug conjugate

  • Pfizer Takes New Direction With Protalix Pact.  // Chain Drug Review;12/7/2009, Vol. 31 Issue 21, p75 

    The article reports on the agreement among Protalix Ltd. and Pfizer Inc. to market expensive medications for the treatment of Gaucher's disease.

  • Quark Biotech earns patent.  // Crain's Cleveland Business;8/5/2002, Vol. 23 Issue 31, p12 

    Reports the patent given to Quark Biotech Inc. for developing a method to identify genes encoding secreted and membranal proteins in Cleveland, Ohio.

  • Harvard, Merck partner on AMD therapies.  // Ophthalmology Times;8/15/2006, Vol. 31 Issue 16, p34 

    The article reports on the license deal between Harvard Medical School and Merck & Co. Inc. to formulate potential therapies for macular degeneration in the United States. Harvard would provide Merck with licenses to specific molecules that may retard the production of lipofuscins, a risk factor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics